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showed that the prevalence of HCV infection in Kerman is
more than other provinces of Iran.
Conclusion: In contrast with other studies HBV-DNA in
these patients could not be detected, hence, it seems that228 14
iral load >104 copies/ml, 3 of them were simultaneously
BeAg positive.
Conclusion: The prevalence of HBV infection in pregnant
omen in eastern Slovakia exceeds the overall estimated
lovak prevalence, and in districts with higher Roma popula-
ion conﬁrms presumed higher prevalence of HBV infection
n this population. Majority of infected women are HBsAg
arriers, but we have conﬁrmed several cases of pregnant
omen with high viral load and increased risk of vertical
ransmission. We consider evaluation of ALT in pregnancy as
nsufﬁcient for ruling out chronic hepatitis B. This study was
upported by VEGA grant No.1/0050/08.
oi:10.1016/j.ijid.2010.02.1994
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ew approaches in in-vitro diagnosis of Hepatitis C infec-
ions: The diagnostic performance of new hepatitis C virus
ore antigen detection test
. Kocazeybek1, P. Yuksel1,∗, S. Saribas1, R. Caliskan1, S.
rgin1, M. Aslan1, A. Yalcıner2, M.M. Torun1
Istanbul University Cerrahpasa Faculty of Medicine,
urkey, Turkey
Duzen Laboratory, Istanbul, Turkey
Background: There are problems currently in the diag-
osis of hepatitis C infections We aimed to investigate the
iagnostic performance of new HCV Ag (Abbott Diagnostic,
ermany.
Methods: All of the study cases were applied to the
stanbul University Microbiology and Clinical Microbiology
epartment and to the Düzen laboratory between February
008-March 2009. Molecular (real-time PCR) and serological
ethods (Micro-ELISA) were applied to the all of the cases,
23 HCV RNA-positive and anti-HCV positive cases, 48 HCV
NA negative and anti-HCV negative cases were included
s the study and negative control groups, respectively. We
valuated sensitivity, speciﬁcity, positive predictive (PPV)
nd negative predictive (NPV) values, accuracy and kappa
alues of antigen detection HCV Ag kit which includes mon-
clonal anti-HCV antibodies against HCV core antigen coated
n the solid phase.
Results: Sensitivity, speciﬁcity, PPV, NPV, accuracy and
appa values were evaluated as 94.3%, 97.9%, 99.1%, 87%,
5.3% and 88%, respectively for HCV Ag kit.
Viral load distrubition and HCV Core Ag results of HCV
NA Positive Patients
CV RNA (IU/ml) HCV RNA Positive Patients
—1000 4
001—2000 2
001—10000 2
0001—100000 13
00001 and upper 102
otal 123Conclusion: As a result, the diagnostic performance
arameters of recently developed HCVAg kit have not satis-
actory results because false negative ratio was 5% and NPV
as 87%. We suggest that this situation is related with unsuf-ternational Congress on Infectious Diseases (ICID) Abstracts
cient analytic sensitivity especially for HCV cases which
ave a 2000 IU/ml and below viral load. We suggest that the
e-evaluation of the sensitivity of this kit will be usefull for
lood screening.
oi:10.1016/j.ijid.2010.02.1995
3.014
o detected hepatitis B virus-DNA in thalassemic patients
nfected by hepatitis C virus in Kerman province of Iran
. Hassanshahiraviz
Faculty of medicine, rafsanjan, kerman, Iran, (Islamic
epublic of)
Background: Occult hepatitis B infection (OBI) is charac-
erized as a form of hepatitis in which despite of absence
f detectable hepatitis B surface antigen (HBsAg), HBV-DNA
s present in patient’s peripheral blood. This project was
imed to investigate the prevalence and clinical impact of
ccult HBV infection in thalassemic patients with chronic
CV infection.
Methods: In this cross-sectional study we have totally
xamined 60 patients suffering HBV and HCV infections by
CR and RT-PCR methods, respectively, in Kerman province
f Iran. ELISA technique (RADIM, Italy) was used to detect
nti-HBc, anti-HBs and HBsAg. The serum level of liver
nzymes (SGOT, SGPT, DB, TB and ALK) were analyzed in
he HCV infected patients (MAN, IRAN). Statistical analyses
erformed using t-test and Chi-square.
Results: We found that 27 cases (out of 60) were infected
y HCV but HBV-DNA was not seen in HCV infected patients.
ur ﬁndings also showed that none of samples were HBsAg
ositive but 9 (33%) (out of 27) HCV-RNA positive patients
ere anti-HBc positive and 11 (40.7%) were positive for
nti-HBs. We found that SGOT, SGPT, DB, TB and ALK are
bove normal in 27 (100%), 19 (70.3%), 12 (44.5%), 15 (55.5%)
nd 15 (55.5%) RNA-HCV positive patients, respectively. The
revalence of hepatitis C infection is very high in tha-
assemic patients and based on other studies our results
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risk factor for the development of signiﬁcant and advanced
ﬁbrosis. Their alterations during antiviral treatment allow
monitoring the progression of liver ﬁbrosis.
doi:10.1016/j.ijid.2010.02.199814th International Congress on Infectious Diseases (ICID) Abs
occult HBV infection isn’t frequent in Iranian thalassemic
patients who suffering from chronic HCV infection.
doi:10.1016/j.ijid.2010.02.1996
53.015
Genotypes and reverse transcriptase variability in asymp-
tomatic chronic hepatitis B virus
M. Basaras1,∗, E. Arrese1, S. Blanco2, P. Ruiz2, R. Cisterna3
1 University of Basque Country, Bilbao, Spain
2 Basurto Hospital, Bilbao, Spain
3 Basurto Hospital. University of Basque Country, Bilbao,
Spain
Background: Genomic mutations presented during hep-
atitis B virus (HBV) reverse transcription could explain its
genetic diversity and account for genetically distinct eight
genotypes which show distinctive geographically distribu-
tion. The main objectives of this study were to determinate
the prevalence of hepatitis B virus genotypes in asymp-
tomatic chronic hepatitis B patients without treatment,
and to identify mutations associated to nucleos(t)ides ana-
logues.
Methods: Twenty two serum samples from asymptomatic
chronic hepatitis B patients without treatment were ana-
lyzed using INNO-LIPA HBV Genotyping assay and INNO-LIPA
HBV DRv2 assay (Innogenetics). Nucleic acid was isolated
and quantiﬁed using real time PCR assay COBAS Taqman HBV
test. HBsAg, anti-HBs, HBeAg and anti-HBe were determined
by ADVIA Centaur.
Results: Genotype D was the most prevalent (45.5%) fol-
lowed by genotype A (27.3%) and genotype E (9%). There
were four coinfection cases (18.2%) (two D/H, one E/F and
one A/D genotypes). Both patients infected with genotype
E were from sub-Saharan area. In our study, all the patients
were positive for HBsAg and negative for HBeAg. HBV-DNA
levels were quantiﬁed and themean was 3.4 log10 copies/ml
(minimum 1.07 and maximum 7.04). Among the twenty two
HBV chronic inactive carriers, in only one case was detected
a single mutation in rtV214A position, which has been asso-
ciated to adefovir dipivoxil treatment. In this case, patient
was infected with genotype D. In the remaining patients no
mutations were identiﬁed at reverse transcriptase domain.
Risk factors for HBV acquisition were as follow: vertical
(27.3%), transfusion (13.6%), sexual (9.1%), tattoos (4.5%),
interfamilial (4.5%) and unknown (41%).
Conclusion: INNO-LIPA is a convenient tool for detec-
tion HBV genotype and resistance mutation. Genotype D
was the most prevalent accompanied with genotype A in
asymptomatic patients, but also coinfection genotypes are
frequent. A resistant mutation is rare in asymptomatic
patients but it was detected in one patient, indicating a
possible predisposition to adefovir dipivoxil therapy resis-
tance. HBV reverse transcriptase gene sequencing analysis
provides additional insight as part of monitoring program
that includes genotypic analysis and quantiﬁcation of circu-
lating virus.
doi:10.1016/j.ijid.2010.02.1997ts e229
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ntiviral treatment with interferon alpha and ribavirin
nﬂuences serum markers of liver ﬁbrosis in children with
hronic hepatitis C
. Mania, W. Sluzewski ∗, P. Kemnitz, M. Figlerowicz, A.
owala-Piaskowska
University of Medical Sciences, Poznan, Poland
Background: Liver ﬁbrosis largely inﬂuences the course
nd prognosis of chronic hepatitis C (CHC). Although per-
utaneous liver biopsy is a valuable tool in the evaluation
f liver injury, it posses signiﬁcant drawbacks that limit
epeated use of this technique. The aim of this study was
o assess chosen serum markers of liver ﬁbrosis — laminin
LAM), hyaluronic acid (HA) and transforming growth factor
eta 1 (TGF-beta-1) with their relation to histopathological
ndings as well as their alterations after antiviral treatment
ith recombinant interferon alpha (IFN-alpha) and ribavirin
Rib) in children with CHC.
Methods: Study group included 68 children, age range
—18 years (mean 13,34± 3,27 years) with diagnosed CHC.
istory data were analysed. Diagnosis was conﬁrmed by the
resence of HCV-RNA in serum by RT-PCR. All children under-
ent histopathological evaluation of liver biopsy specimen
ccording to Ishak scoring system. Serum sample and liver
iopsy specimen were collected the same day. LAM, HA
nd TGF-beta-1 were measured in serum by enzyme linked
mmunosorbent assay kits. Children were treated with IFN-
lpha (3 MU/m2 3 x/week in s.c. injections) and Rib (orally,
wice daily) for 48 weeks. Serum markers of ﬁbrosis were
lso assessed at the end of the treatment.
Results: Length of infection was 7.34± 4.03 years (range
—13.5 years). Mean ALT activity was 60,82± 65,02 IU/l.
ncreasing mean serum TGF-beta-1 (p = 0.029) and decreas-
ng mean LAM level (p = 0.039) was found in the groups of
hildren with increasing stage of ﬁbrosis. Level of LAM was
eﬁned a risk factor of signiﬁcant ﬁbrosis (95%CI 18.05;
7.87, p = 0.001), while level of TGF-beta -1 of signiﬁ-
ant (95%CI: -33.51;-1.73, p = 0.030) and progressed liver
brosis (95%CI -36.09; -3.37, p = 0.019). Conducted antivi-
al treatment with IFN-alpha and Rib resulted in signiﬁcant
ecrease of TGF-beta-1 (51.42± 30.68 vs. 35.24± 31.50
g/ml, p = 0.032) and increase of LAM (60.26± 52.38 vs.
3.70± 46.25 ng/ml, p = 0.002) in serum. No signiﬁcant
lterations were detected in the control group of untreated
hildren.
Conclusion: Level of liver injury in children with CHC
aries in severity. TGF-beta-1 and LAM are not only propor-
ional to the stage of ﬁbrosis but also seem to be a good
